Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin

NEW YORK, October 29, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.

--
GlaxoSmithKline plc Research Reports
On October 22, 2014, GlaxoSmithKline plc (GlaxoSmithKline) announced its Q3 2014 financial results. On the basis of constant exchange rates (CER), the Company reported turnover of GBP5.6 billion, down 3% YoY. Based on CER the Company's' Core operating profit declined 1% YoY to $1.9 billion, while core EPS increased 5% YoY to GBP0.28, helped by targeted cost reductions and financial efficiencies. GlaxoSmithKline added that for Q3 2014, it has maintained a dividend of GBP0.19 per share and expects the full year 2014 dividend to grow 3% YoY to GBP0.80. Further, it continues to anticipate FY 2014 core EPS based on CER to be nearly in line with that of 2013. The Company informed that its proposed 3-part transaction with Novartis is on track for completion in H1 2015. The full research reports on GlaxoSmithKline are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/GSK/report.pdf

--
IDEXX Laboratories, Inc. Research Reports
On October 24, 2014, IDEXX Laboratories, Inc. (IDEXX) announced its Q3 2014 earnings results. Revenue stood at $383.5 million, up 13.4% YoY. The Company reported net income of $52.1 million or $1.03 per diluted share, compared with $45.7 million or $0.86 per diluted share in Q3 2013. Adjusted diluted EPS came in at $1.05, versus $0.84 in Q3 2013. Jonathan Ayers, Chairman and CEO of IDEXX said, "We achieved exceptional growth across our business in the third quarter, reflecting benefits from our investments in our global commercial capability and innovation pipeline. Normalized CAG Diagnostics recurring revenues grew organically over 11% in the US and 15% in international markets, supported by strong gains across our modalities." For full-year 2014, IDEXX expects adjusted EPS to be in the range of $3.85-$3.90. The full research reports on IDEXX are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/IDXX/report.pdf

--
BioMarin Pharmaceutical Inc. Research Reports
On October 23, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced its Q3 2014 financial results. Total revenue was reported at $176.8 million versus $136.9 million in Q3 2013. Net product revenue from VIMZIM stood at $25.2 million while the same from Naglazyme and Kuvan increased 6.8% YoY and 22.5% YoY to $67.5 million and $53.4million, respectively. Net income was $7.4 million, or $0.05 per diluted share, compared to net loss of $53.0 million, or $0.38 loss per diluted share in Q3 2013. Jean-Jacques Bienaimé, CEO of BioMarin said, "The commercial launch of VIMIZIM continues to make excellent progress," he added, "We believe that the continued growth of our five commercial products will help BioMarin reach over $1 billion in revenues over the next 2-3 years." For full-year 2014, the Company has increased its revenue guidance to a range of $700 to $710 million, from its previous estimated range of $680 to $700 million. The full research reports on BioMarin are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/BMRN/report.pdf

--
General Electric Company Research Reports
On October 24, 2014, General Electric Company (GE) reported that its unit GE Healthcare Life Sciences (GE Healthcare ) has won a BioProcess International (BPI) industry award for excellence in bioprocessing facility design, at a special ceremony during the 2014 BPI International Conference and Exhibition in Boston, Massachusetts, USA. According to the Company, the BPI awards recognize outstanding products, services, partnerships and people that have had the greatest positive impact across the biopharmaceutical manufacturing industry. The Company informed that GE Healthcare's winning entry was - "Excellence in Facility Design or Retrofit" for GE Healthcare and Gallus BioPharmaceuticals1. Nigel Darby, Vice President, BioProcess, GE Healthcare, commented, "Winning this award and being a finalist in three other categories is both a great honor and great recognition of the talent, hard work, and commitment to excellence of our GE Healthcare Life Sciences team." The full research reports on GE are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/GE/report.pdf

--
Lockheed Martin Corporation Research Reports
On October 21, 2014, Lockheed Martin Corporation (Lockheed Martin) announced its Q3 2014 earnings results. Net sales stood at $11.1 billion, compared to $11.3 billion in the Q3 2013. Net earnings from continuing operations were reported at $888 million, or $2.76 per diluted share, compared to $842 million, or $2.57 per diluted share, in Q3 2013. Chairman, President and CEO of Lockheed Martin, Marillyn Hewson said, "Although we continue to face global economic challenges, our program and operational performance this quarter resulted in increased earnings per share and strong cash generation. As we look ahead to 2015, we will remain focused on delivering for our customers, returning value to our shareholders, advancing our technologies and investing in our people." For 2014, the Company anticipates net sales to be approximately $45 billion and diluted EPS to be nearly $11.15. The full research reports on Lockheed Martin are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/LMT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review